Alterity Therapeutics Ltd. reported positive top-line phase II results for lead candidate ATH-434 for treating multiple ...

MST Financial is managing the raise and has split it into two tranches. Shares were placed in a trading halt on Thursday.

(Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics ...

for fast-track approval of its treatment for multiple system atrophy (MSA). Alterity shares soared up to 112% this morning ...

As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 ...

As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase ...

MPs and campaigners say that people suffering from Motor Neurone Disease or Parkinson’s should have greater access to an ...

placebo-controlled Phase 2 clinical trial in patients with early-stage multiple system atrophy (MSA). The topline data showed that ATH434 produced clinically and statistically significant improvement ...

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares ...